Clinical trials: sponsored by Glaukos Corporation
Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
iDose TR Administration in an Office-Based Surgery Setting
Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.
- Trial name
- NCT07816692
- Testing
- iDose TR (travoprost intracameral implant) 75 µg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glaukos Corporation
Glaucoma
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07075718
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Glaukos Corporation
Keratoconus
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
- Trial name
- NCT07629557
- Testing
- Riboflavin Ophthalmic Solutions, UV-A Irradiation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle
Travoprost Intraocular Implant + iStent Infinite
Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and…
- Trial name
- NCT06066645
- Testing
- Travoprost Intraocular Implant, iStent infinite
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Glaukos Corporation
Glaucoma
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07495852
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Glaukos Corporation
Demodex Blepharitis
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
- Trial name
- NCT07400965
- Testing
- GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
- Trial name
- TRIO (NCT07400926)
- Testing
- Travoprost
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glaukos Corporation
Keratoconus
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
- Trial name
- NCT07400952
- Testing
- GLK-221 Ophthalmic Solution
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-angle, Ocular Hypertension (OHT)
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
- Conditions
- Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
- Trial name
- NCT06848946
- Testing
- iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Glaukos Corporation
Persistent Corneal Epithelial Defect
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED).
- Trial name
- NEXPEDE-1 (NCT05966493)
- Testing
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Where
- 28 sites in United States, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- Glaukos Corporation
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03868124
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03519386
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Performance of the Travoprost Intraocular Implant
To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid…
- Trial name
- NCT06582732
- Testing
- Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6
- Where
- Armenia
- Volunteers
- 210 people
- Sponsor
- Glaukos Corporation
Glaucoma, Glaucoma, Open-Angle
Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor
- Trial name
- NCT05127551
- Testing
- iStent Infinite, Competitor Device
- Where
- Canada
- Volunteers
- 179 people
- Sponsor
- Glaukos Corporation
Progressive Keratoconus
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
- Trial name
- NCT05314738
- Testing
- NXL Energy 1, NXL Energy 2, NXL Energy 3
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma, Ocular Hypertension
Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable.
- Trial name
- NCT06061718
- Testing
- iDose TR
- Where
- Armenia
- Volunteers
- 60 people
- Sponsor
- Glaukos Corporation
Corneal Ectasia
Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery
The objectives of this post market registry are to evaluate the safety and durability of treatment effect up to 3 years following cross-linking performed with Photrexa Viscous (riboflavin 5'- phosphate in 20% dextran ophthalmic…
- Trial name
- CXL (NCT03319082)
- Testing
- Corneal Collagen Cross-linking
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Glaucoma
iStent Inject New Enrollment Post-Approval Study
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
- Trial name
- NCT04624698
- Testing
- iStent Inject Implantation
- Where
- 3 sites in United States
- Volunteers
- 358 people
- Sponsor
- Glaukos Corporation
Progressive Keratoconus
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus.
- Trial name
- NCT03442751
- Testing
- Test Article A, Test Article B, KXL medical device system
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Glaukos Corporation